Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Sep 24, 2026
Penumbra Inc (PEN)
A forensic read on Penumbra Inc built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
C · Mixed — selective
Forensic grade
Safe
Financial health
17.4
Distress distance
Clean
Earnings quality
4
Forensic signals
77.9
P / E (ttm)
12.4%
ROE
$12.6B
Market cap
17.5%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence, going concern, valuation). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Penumbra Inc earns a C (Mixed — selective) forensic quality grade, and its balance-sheet distress test reads 17.4, placing it in the Safe zone. 4 forensic signals were flagged in its latest SEC filings, led by accruals ratio (% of noa).
What the filings flag
+40.1%
FY2024→FY2025
Accruals ratio (% of NOA).Net operating assets grew +40.1% relative to their own average in FY2025 — scaled by NOA itself, not by total assets, which is what the Forensic Screens card's own accrual row divides by. Accruals are building sharply — a large slice of profit sits in operating assets, not cash. An accrual is a claim that still has to be collected or written down, so the gap resolves in a later period whichever way it goes. The build is led by receivables up +13% against revenue +17%. A cash-flow measure on the same base disagrees: reported earnings ran behind operating cash by 6% of net operating assets, against an accruals ratio of 40.1%. The two are computed differently: the accruals ratio is the change in net operating assets over average net operating assets, while the cash-flow figure is net income less operating cash flow over that same average. Read them as two results, not one.
stopped
FY2024→FY2025
Shareholder returns — halted.Capital returns have STOPPED — $100M of buybacks + dividends in FY2024, but ~$0 in FY2025. A halt usually means the company is conserving cash.
11.3%
FY2025
Return on invested capital.Return on invested capital is 11.3% in the latest fiscal year, against 5% in FY2023, having run between 0.6% and 11.3% across FY2023–FY2025 with no direction held. The capital base behind it grew +18% across FY2023–FY2025, from $1.2B to $1.5B, and the return did not fall doing it, so the dollars added over that window earned at least the 5% the older base was already earning.
+0.1%/yr
FY2023–FY2025
Share count.Diluted share count changed 0% over the last 2 years to FY2025 (+0.1%/yr). Roughly flat — the count is neither shrinking nor growing meaningfully. Per-share value isn't being meaningfully helped or hurt by the count.
Key fundamentals
Latest Revenue$1.40B
Revenue Growth YoY+17.5%
Revenue CAGR (2yr)+15.1%
Net Margin12.7%
Free Cash Flow$174.9M
Return on Equity12.4%
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Penumbra Inc's actual 10-K/10-Q/8-K filings?